HeartShare 2.0: Refining Heart Failure Subtypes and Treatment Targets for Personalized Clinical Trials - Clinical Trial Center and Clinical Centers (U01 Clinical Trial Optional)
Grant Opportunity Analysis
The National Institutes of Health, through HHS, is seeking cooperative agreement applications for HeartShare 2.0 to refine heart failure with preserved ejection fraction subtypes and treatment targets for personalized clinical trials. The program will support a new Clinical Trial Center and up to seven Clinical Centers, with the CTC handling master protocol development, project management, recruitment oversight, performance milestones, and scientific conduct, while the CCs recruit and retain patients and controls, perform deep phenotyping and longitudinal follow-up, obtain tissue biopsies, and support future trial recruitment. The effort is organized around collaborative HFpEF research and data sharing, with applications limited to either the CTC or a CC and requiring different principal investigators; the maximum project period is six years, and non-domestic entities are not eligible although foreign components of U.S. organizations are allowed. Applications are due July 9, 2026, with an award ceiling of $500,000 and estimated total program funding of $3,465,000 across eight awards.
Eligible Applicants
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.